Abstracts

Key Take-Away:

This study confirmed the evidence that dydrogesterone effectively reduced dysmenorrhea pain symptoms and did not repress ovulation during oral administration. This is the 1st study to establish that dydrogesterone is the only hormonal drug which can be permitted to get pregnant during its administration. It also renders efficacy and safety for the treatment of endometriosis with dysmenorrhea. 

Introduction:

The efficacy and safety of dydrogesterone in Japanese women suffering from dysmenorrhea has been evaluated in this study.

8min read    
Key Take-Away:

This retrospective review by Ryan J Diel et al. depicted that photophobia and dry eye symptom improvement after administration of BoNT-A injections in patients treated for migraine pain occurred independent of baseline tear volume at the baseline. The modulation of shared trigeminal neural pathways may play a crucial role in the same.

Introduction:

To examine the efficacy of botulinum toxin A (BoNT-A) in decreasing photophobia and dry eye symptoms in patients with chronic migraine. Also, the investigators focused on evaluating tear film volume as a promising contributor to the symptoms in these migraine patients.

8min read    
Key Take-Away:

Pregabalin belongs to the class of anticonvulsants, which works by reducing the number of pain signals sent out by impaired nerves in the body. All the analyses of pain and sleep scores (MMRM and LOCF) in this study were significant at all time points for subjects with type 2 diabetes mellitus. 

Introduction:

This study aimed to compare the efficacy and safety of pregabalin for painful diabetic peripheral neuropathy (pDPN) in type 1 (T1DM) or 2 diabetes mellitus (T2DM) subjects.

8min read    
Key Take-Away:

Albilia JB DMD et al. found out that intra-articular injections of liquid PRF appear to have significant analgesic effects lasting for 12 months in patients with localized painful internal derangement of the temporomandibular joint (TMJ), which is only one of many synovial joint diseases. In this preliminary investigation, patients suffering from Wilkes' stage IV (intermediate-late) and stage V (late) respond the best to this particular second-generation blood concentrate.

Introduction:

To examine the clinical advantages of liquid platelet-rich fibrin (PRF) in patients with temporomandibular joint (TMJ) pain and dysfunction.

6min read    
Key Take-Away:

This is the first study which compared baricitinib 2 mg versus 4 mg in patients with rheumatic arthritis (RA). The total adverse events, discontinuation of the drug due to adverse events, malignancies, major adverse cardiac events, infections like herpes zoster, and serious infections were significantly higher between the two doses of Baricitinib at 24 weeks follow-up.

Introduction:

On 23 April 2018, the FDA-based Advisory Committee approved the use of baricitinib 2 mg for RA treatment and suggested the possibility of serious adverse events associated with baricitinib 4 mg. Therefore, the authors aimed to systematically distinguish between the risk of adverse drug events observed with baricitinib 2 mg against 4 mg for the treatment of RA patients.

9min read